调脂药在肾脏病中的合理应用

Reasonable application of antilipemic agents in patients with kidney diseases

目前,我国高脂血症发病率逐年增高,资料显示,血脂异常患病率已高达18.2%,已成为我国居民的一个重要公共卫生问题。临床研究证实,慢性肾脏病和血脂异常关系密切,两者相互促进,互为因果,理想的血脂水平有助于改善慢性肾脏病(CKD)患者的长期预后。CKD患者血脂异常,首先应调整生活方式,积极治疗原发病,重点强调的是根据血脂异常的不同类型,合理选用调脂药物,以达靶目标值,从而延缓CKD病程的进展。

Currently, the morbidity of hyperlipemia in our country has increased year by year. And data showed that the prevalence of dyslipidemia has been as high as 18.2% , which has become an important public health problem of residents in our country. Clinical studies have confirmed that dyslipidemia is closely related to chronic kidney disease （ CKD ）. They cause, affect, and promote each other. Ideal lipid level helps to improve the longterm prognosis of patients with CKD. CKD patients with dyslipidemia, first of all, should adjust the life style and had their primary diseases treated actively. What is important is to reasonably select antilipemic agents according to the different types of dyshpidemia, in order to achieve the target value and delay the progression of CKD course.